Companies / BOC Sciences / Icrucumab
BOC Sciences

Icrucumab | BOC Sciences

Icrucumab is a human monoclonal antibody directed against vascular endothelial growth factor receptor-1 (VEGFR-1). Icrucumab inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling, making icrucumab an attractive candidate for antitumor activity.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.